Analysis of overall survival and disease-specific survival in the TCGA-PAAD dataset revealed that patients with high FOXP1 expression had significantly lower survival rates, signifying that FOXP1 is a prognostic marker in pancreatic cancer (Fig. 1E). Here, FOXP1 is linked to pancreatic neoplasm.